Catalent buys Italian manufacturing facility from BMS

Jan. 7, 2020

Catalent has bought an oral solid, biologics and sterile product manufacturing and packaging facility in Anagni, Italy, from Bristol-Myers Squibb. This completes BMS's previously announced divestment of the facility.

According to BMS, the divestiture is part of its strategy to simplify and to realign its business portfolio to address changes in its business and the future requirements of its pipeline. The company is focusing resources on discovering, developing and delivering transformational medicines for patients facing serious diseases.

The Anagni facility manufactures and packages cardiovascular, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics. 

Read the full Bristol-Myers Squibb release